Share from 0:00
0:00
/
0:00
Transcript
Thanks for having me. Can you see my screen? No, just kidding, just kidding. We've done this enough so you should see it. I'm going to talk about a case of driver mutation lung cancer. It's nice to meet you all. I'm Vinay Prasad. I'm a professor here who attends at San Francisco General Hospital and works in epidemiology.
All right, let's get started. I have a bunch of learning objectives. I don't know how many we're going to get through, but we'll see what we can do. One question I always have and people talk about is, is driver mutation lung cancer better than non-driver mutation lung cancer?
Is single agent pembrolizumab ideal for someone who doesn't have driver mutations but has a PD-L1 expression of over 50%, let's say 55%? Why is disease control rate and overall survival actually unreliable in single-arm studies? Are waterfall plots visually accurate? How much time does surrogate approval save? How often are control arms in randomized trials suboptimal?
Share this post